CRYAB and myeloid sarcoma: When considering the outcome of the present Phase IIa study, apart from the intravenous route of HspB5 administration, the use of sub-immunogenic dose levels, and the active induction of tolerogenic macrophage factors by HspB5, also the temporal profile of clinical responses to treatment in MS patients is therefore consistent with tolerance induction via activation of peripheral regulatory T cells.